🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

64 results for “PTC” Clear

  1. Ataluren + Pembrolizumab

    PTC THERAPEUTICS, INC.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  2. CNSA-001

    PTC THERAPEUTICS, INC.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  3. EPI-589

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  4. EPI-743

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial

  5. Eladocagene Exuparvovec

    PTC THERAPEUTICS, INC.

    AADC Deficiency

    phase 2 gene therapy active

    1 trial

  6. Lenalidomide

    First Tracks Biotherapeutics

    PTCL, NOS

    phase 2 small molecule active

    1 trial

  7. Lenalidomide and Gemcitabine (Dose level 11)

    China SXT Pharmaceuticals

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  8. NEXPOVIO 20 mg film-coated tablets, HOLOXAN 1 g polvere per soluzione per infusione, Decadron “8 mg/2 ml Soluzione iniettabile”, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione.

    Fondazione Telethon ETS

    Relapsed or Refractory Peripheral T-cell Lymphomas

    phase 2 small molecule active

    1 trial

  9. PTC124

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  10. PTC124

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  11. PTC299

    PTC THERAPEUTICS, INC.

    Neurofibromatosis 2

    phase 2 small molecule terminated

    1 trial

  12. PTC518

    PTC THERAPEUTICS, INC.

    Huntington Disease

    phase 2 small molecule completed

    1 trial

  13. PTC857

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial

  14. PTC857, Placebo to match PTC857 60 mg/mL oral solution, Utreloxastat 62.5

    PTC THERAPEUTICS, INC.

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule active

    1 trial

  15. PTC923

    PTC THERAPEUTICS, INC.

    BH4 Deficiency

    phase 2 small molecule completed

    1 trial

  16. Placebo

    PTC THERAPEUTICS, INC.

    Friedreich's Ataxia

    phase 2 small molecule completed

    1 trial

  17. Placebo

    PTC THERAPEUTICS, INC.

    Leigh Syndrome

    phase 2 small molecule completed

    1 trial

  18. Placebo to match 5-mg PTC518 tablets, Placebo to match 20-mg PTC518 tablets, PTC518, PTC518

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  19. Romidepsin

    Fondazione Telethon ETS

    Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell lymphoma, NOS

    phase 2 small molecule active

    1 trial

  20. Selinexor

    Karyopharm Therapeutics

    Peripheral T-cell Lymphoma (PTCL)

    phase 2 small molecule terminated

    1 trial

  21. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Kaposi's Sarcoma

    phase 2 small molecule terminated

    1 trial

  22. ataluren

    PTC THERAPEUTICS, INC.

    Epilepsy

    phase 2 small molecule completed

    1 trial

  23. gene therapy

    PTC THERAPEUTICS, INC.

    Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

    phase 2 small molecule completed

    1 trial

  24. A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma

    Kyowa Kirin Holdings B.V.

    T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources